AGIPHARM

AGIPHARM presentation 

 Created in 1992 to bring together French subsidiaries of American pharmaceutical laboratories, the Association of International Groups for Research Pharmacy (AGIPHARM) represents the American geographic family within LEEM (Les Entreprises du Médicament), the professional organization of pharmaceutical companies in France.

The association brings together companies that have succeeded, beyond their American origin, have a common vision and have a recognized expertise in the field of therapeutic innovation. It positions itself as a force for proposals to decision-makers and authorities to promote France's place on the international scene of scientific and medical research, while helping to strengthen patients' access to therapeutic innovation in France.

To date, AGIPHARM brings together 14 member companies from among the most important global pharmaceutical players, leaders in pharmaceutical innovation: AbbVie, Amgen, Biogen, Blueprint Medicines, BMS, CSL Behring, Gilead, Incyte, Janssen, Lilly, MSD, Pfizer, Seagen and Vertex.

The coordination and representation of AGIPHARM is ensured by its Executive Secretary General, Guillaume BOUCHARA, with the support of the NEXTEP cabinet of which he is the President.

Our values and ambitions

The Association of International Groups for Research Pharmacy (Agipharm) brings together the French subsidiaries of the 14 main American pharmaceutical laboratories located in France. Nearly 9,000 employees (1) of our companies work daily on the national territory in the service of therapeutic innovation and the improvement of patient care.

Committed to the values of ethics and responsibility, we advocate a transparent and fruitful dialogue with healthcare professionals, patient associations and public authorities (2).

The ambition of Agipharm is to contribute constructively to the public debate, with all of the stakeholders in our health system, in order to improve patient access to therapeutic innovation and guarantee availability. of the largest number of French patients with the best therapies available.

We thus wish to participate in the reflections relating to the strengthening of the attractiveness of our health system, to the influence of French clinical research and to the sustainability of our social model, to which we are, as industrialists and as French citizens, deeply attached.
(1) Agipharm survey of its members - June 2020.
(2) In order to ensure the transparency of our links with public officials, Agipharm is listed in the directory of interest representatives of the High Authority for Transparency of Public Life.

The footprint in France

Members of AGIPHARM

Stéphane LASSIGNARDIE, President

AbbVie is an international research-based biopharmaceutical company. Its mission is to provide its expertise, human resources and a unique approach to innovation in order to develop innovative therapies responding to serious or chronic diseases in four priority therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie also remains involved in historic therapeutic areas such as anesthesia and neonatology.

Present in 75 countries, the AbbVie Group employs more than 30,000 people worldwide.

Corinne BLACHIER-POISSON, President

World leader in biotechnology, Amgen innovates to treat patients suffering from serious illnesses by using living resources to design targeted therapies. This approach is based on cutting-edge technologies, such as human genetics, which characterize the molecular mechanisms that cause disease. Amgen focuses its research on pathologies whose medical needs remain significant.

On French territory since 1990, Amgen France celebrates its 30th anniversary in 2020. The company now has 400 employees. With 13 biomedicines * and numerous partnership initiatives, it works to progress in the management of cancer, cardiovascular, inflammatory and renal diseases. With 36 active studies on 15 molecules, involving 905 patients at nearly 257 sites (2019 figures), France is also one of the countries where Amgen has the most significant clinical research activity.

Beyond the drug, Amgen is committed to developing solutions to optimize patient care. This approach is based on the identification of ruptures within the care paths and on the implementation of adapted and co-constructed actions.

Marina VASILIOU, President

Biogen's mission is clear: to be pioneers in neuroscience. Biogen discovers, develops, and offers patients around the world innovative therapies for the treatment of serious neurological and neurodegenerative diseases and related therapeutic areas.

Founded in 1978 by Charles Weissman, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen is one of the world's leading biotechnology companies.

Biogen currently has the broadest therapeutic offer against multiple sclerosis (MS) in the industry, has developed the first treatment authorized in spinal muscular atrophy, and provides patients and healthcare professionals with innovative biosimilar treatments from the latest advances in biotechnology. Biogen is committed to advancing research in multiple sclerosis and neuroimmunology, in neuromuscular disorders, movement disorders, Alzheimer's disease and related diseases, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.

Hélène Thomas, Regional Vice President and General Manager EU North

Blue Print is a global precision medicine company focused on designing targeted therapies that aim to significantly improve the lives of patients at all stages of disease.


Through our proprietary compound library, drug design capabilities and molecular targeting expertise, we rapidly and reproducibly translate science into medicine. 


Today, we make our therapies available worldwide, and are developing several research programs in genetically determined cancers, hematological disorders and cancer immunotherapy.

Christophe DURAND, President

Since November 20, 2019, Bristol-Myers Squibb and Celgene have formed a single company worldwide. In France, for the coming months, the Bristol-Myers Squibb and Celgene subsidiaries will remain two separate legal entities until they are combined.

Bristol Myers Squibb is an international biopharmaceutical company whose mission is to discover, develop and offer innovative medicines that help patients overcome serious illnesses. To find out more about Bristol Myers Squibb, visit www.BMS.fr/com or follow us on YouTube and Twitter @BMSFrance.

Celgene SAS is a company whose mission is to provide innovative treatments in pathologies for which medical needs are important and not covered and thus transform the lives of patients with serious or disabling diseases.

Franck PUGET, President

CSL Behring is a global biotechnology pharmaceutical laboratory founded over a century ago that markets innovative biotherapies dedicated to the care of patients with rare and serious diseases.

CSL Behring is one of the world leaders in the research, production and provision of therapeutic proteins derived from blood plasma or manufactured by genetic recombination technologies. In France, CSL Behring is the leading supplier of polyvalent immunoglobulins.

Our mission is to discover, develop and provide innovative therapies that improve the quality of life for patients. Innovation is in the DNA of CSL Behring: looking to the future, our teams have a priority in designing the drugs of tomorrow, including gene therapy.

Michel JOLY, President

Gilead Sciences : driven by innovation, serving patients.

Founded in 1987, Gilead Sciences is a pharmaceutical laboratory that creates, develops and provides patients with innovative treatments to meet unmet medical needs.

Gilead's mission is to advance the care of patients with life-threatening illnesses. Based in Foster City, California, Gilead is present in more than 35 countries around the world.

Gilead first specialized in the fight against HIV / AIDS, in particular by providing patients with the first triple therapy in a single tablet, then in liver diseases, with treatments to cure hepatitis C.

In recent years, Gilead has also turned to hematology and oncology, through cell therapy, an innovative treatment for patients in therapeutic impasse. Research continues in all of these areas as well as in chronic inflammatory diseases.

Olivier PILLEY, President

Guided by science,
Patient-centered,

Incyte is an international biopharmaceutical company whose scientific rigor is placed at the center of the discovery, development and availability of innovative drugs.

Incyte is committed to making a difference in the lives of patients by discovering molecules that will meet major medical needs that are not covered, regardless of the incidence of the pathology.

Incyte is particularly active in oncology, hematology and inflammatory diseases with First / Best-in-class molecules marketed and a large R&D portfolio in numerous indications.

Delphine AGUILERA-CARON, President

Janssen's mission is to build a future in which diseases no longer exist. And we are working tirelessly, as a pharmaceutical company of the Johnson & Johnson group, to make this future a reality. We are pushing the boundaries of science to fight disease.

We are ingenious to improve access to care and restore hope. Our efforts are focused on the therapeutic areas in which we can really make a difference: oncology and hematology, immunology, virology and infectious diseases, neuroscience, cardiovascular and metabolic diseases, as well as hypertension pulmonary arterial.

To find out more, visit our website and follow us on Twitter, LinkedIn and YouTube.

Marcel LECHANTEUR, President

Eli Lilly and Company, founded over 140 years ago, is a world leader in health, uniting care and discovery to provide everyone with a better life, everywhere.

Established in France since 1962, the laboratory is present across the entire drug chain, from clinical research to production and commercial operations. The Fegersheim (Bas-Rhin) production site, one of the largest Lilly sites in the world, specializes in injectable treatments, particularly in diabetes and osteoporosis.

Lilly is present in various therapeutic fields, namely diabetes and endocrine diseases, cancer, autoimmune diseases in rheumatology and dermatology, pain syndromes, osteoporosis and psychiatric and neurological diseases.

Clarisse LHOSTE, President

Present in France since 1961, MSD France, a research-based pharmaceutical laboratory, is a subsidiary of the American company Merck & Co., Inc., Kenilworth, NJ, USA.

MSD France aims to provide patients and healthcare professionals with a global innovative healthcare offer, made up of both prescription drugs (mainly in oncology, infectiology and vaccines), and solutions and services, in particular in digital.

Since its creation almost 130 years ago, MSD has placed therapeutic innovation at the heart of its commitment and responsibility. We believe that innovation only makes sense if patients can benefit from it. This is why we believe we have a role to play in ensuring that patients and populations have access to medicines and vaccines that can improve and save lives.

Reda GUIHA, President

 Our vision: Every day, Pfizer works to advance well-being, prevention and treatments to combat the serious diseases of our time and tomorrow. Conscious of our responsibility as a world leader in the biopharmaceutical industry, we are also collaborating with healthcare professionals, authorities and local associations to support and expand access to quality care worldwide. We strive for quality, safety and excellence in the discovery, development and production of our medicines and human health solutions. Our diversified global portfolio includes synthetic or biotechnology molecules, vaccines, but also world-renowned self-medication products.

Our mission: To be recognized as the benchmark for innovative biopharmaceutical companies.

Our raison d'être: Innovate to provide patients with treatments that improve their lives.
Share by: